Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its attendance at the American Thoracic Society Congress, taking place in San Francisco, USA, from 18 to 21 May 2025.
The positive results from the recent analysis of data from studies of NXP002 in a precision-cut lung slice disease models using tissue from IPF and autoimmune ILD patients will be presented on 21 May within the Wednesday morning session titled “Drug Discovery and Development in IPF: Challenges and Opportunities”.
Dr Dan Gooding, Executive Director, Nuformix, said: “We are delighted to be attending the ATS congress in San Francisco. We will have the opportunity to progress discussions with potential licensing and development partners and showcase the positive results from our recent analysis of NXP002’s performance in tissue from multiple IPF and autoimmune ILD patients. This follows the receipt of confirmation of eligibility for Orphan Drug Designation in IPF from the EMA. I look forward to providing further updates in due course as appropriate.”
